Does the GH/IGF-1 axis contribute to skeletal sexual dimorphism? Evidence from mouse studies

Zhongbo Liu, Subburaman Mohan, Shoshana Yakar

Research output: Contribution to journalArticle

Abstract

The contribution of the gonadotropic axis to skeletal sexual dimorphism (SSD) was clarified in recent years. Studies with animal models of estrogen receptor (ER) or androgen receptor (AR) null mice, as well as mice with bone cell-specific ablation of ER or AR, revealed that both hormones play major roles in skeletal acquisition, and that estrogen regulates skeletal accrual in both sexes. The growth hormone (GH) and its downstream effector, the insulin-like growth factor-1 (IGF-1) are also major determinants of peak bone mass during puberty and young adulthood, and play important roles in maintaining bone integrity during aging. A few studies in both humans and animal models suggest that in addition to the differences in sex steroid actions on bone, sex-specific effects of GH and IGF-1 play essential roles in SSD. However, the contributions of the somatotropic (GH/IGF-1) axis to SSD are controversial and data is difficult to interpret. GH/IGF-1 are pleotropic hormones that act in an endocrine and autocrine/paracrine fashion on multiple tissues, affecting body composition as well as metabolism. Thus, understanding the contribution of the somatotropic axis to SSD requires the use of mouse models that will differentiate between these two modes of action. Elucidation of the relative contribution of GH/IGF-1 axis to SSD is significant because GH is approved for the treatment of normal children with short stature and children with congenital growth disorders. Thus, if the GH/IGF-1 axis determines SSD, treatment with GH may be tailored according to sex. In the following review, we give an overview of the roles of sex steroids in determining SSD and how they may interact with the GH/IGF-1 axis in bone. We summarize several mouse models with impaired somatotropic axis and speculate on the possible contribution of that axis to SSD.

Original languageEnglish (US)
Pages (from-to)7-17
Number of pages11
JournalGrowth Hormone and IGF Research
Volume27
DOIs
StatePublished - Apr 1 2016

Fingerprint

Somatomedins
Sex Characteristics
Growth Hormone
Bone and Bones
Estrogen Receptors
Animal Models
Steroids
Hormones
Growth Disorders
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Androgen Receptors
Puberty
Body Composition
Estrogens
Therapeutics

Keywords

  • Bone
  • Growth hormone receptor (GHR)
  • Insulin-like growth factor-1 (IGF-1)
  • Micro-computed tomography
  • Osteocyte
  • Parathyroid hormone (PTH)
  • Skeletal sexual dimorphism (SSD)

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Does the GH/IGF-1 axis contribute to skeletal sexual dimorphism? Evidence from mouse studies. / Liu, Zhongbo; Mohan, Subburaman; Yakar, Shoshana.

In: Growth Hormone and IGF Research, Vol. 27, 01.04.2016, p. 7-17.

Research output: Contribution to journalArticle

@article{c675ea6980bd4a59addd08cda5af5040,
title = "Does the GH/IGF-1 axis contribute to skeletal sexual dimorphism? Evidence from mouse studies",
abstract = "The contribution of the gonadotropic axis to skeletal sexual dimorphism (SSD) was clarified in recent years. Studies with animal models of estrogen receptor (ER) or androgen receptor (AR) null mice, as well as mice with bone cell-specific ablation of ER or AR, revealed that both hormones play major roles in skeletal acquisition, and that estrogen regulates skeletal accrual in both sexes. The growth hormone (GH) and its downstream effector, the insulin-like growth factor-1 (IGF-1) are also major determinants of peak bone mass during puberty and young adulthood, and play important roles in maintaining bone integrity during aging. A few studies in both humans and animal models suggest that in addition to the differences in sex steroid actions on bone, sex-specific effects of GH and IGF-1 play essential roles in SSD. However, the contributions of the somatotropic (GH/IGF-1) axis to SSD are controversial and data is difficult to interpret. GH/IGF-1 are pleotropic hormones that act in an endocrine and autocrine/paracrine fashion on multiple tissues, affecting body composition as well as metabolism. Thus, understanding the contribution of the somatotropic axis to SSD requires the use of mouse models that will differentiate between these two modes of action. Elucidation of the relative contribution of GH/IGF-1 axis to SSD is significant because GH is approved for the treatment of normal children with short stature and children with congenital growth disorders. Thus, if the GH/IGF-1 axis determines SSD, treatment with GH may be tailored according to sex. In the following review, we give an overview of the roles of sex steroids in determining SSD and how they may interact with the GH/IGF-1 axis in bone. We summarize several mouse models with impaired somatotropic axis and speculate on the possible contribution of that axis to SSD.",
keywords = "Bone, Growth hormone receptor (GHR), Insulin-like growth factor-1 (IGF-1), Micro-computed tomography, Osteocyte, Parathyroid hormone (PTH), Skeletal sexual dimorphism (SSD)",
author = "Zhongbo Liu and Subburaman Mohan and Shoshana Yakar",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.ghir.2015.12.004",
language = "English (US)",
volume = "27",
pages = "7--17",
journal = "Endocrinology and Metabolism",
issn = "1096-6374",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Does the GH/IGF-1 axis contribute to skeletal sexual dimorphism? Evidence from mouse studies

AU - Liu, Zhongbo

AU - Mohan, Subburaman

AU - Yakar, Shoshana

PY - 2016/4/1

Y1 - 2016/4/1

N2 - The contribution of the gonadotropic axis to skeletal sexual dimorphism (SSD) was clarified in recent years. Studies with animal models of estrogen receptor (ER) or androgen receptor (AR) null mice, as well as mice with bone cell-specific ablation of ER or AR, revealed that both hormones play major roles in skeletal acquisition, and that estrogen regulates skeletal accrual in both sexes. The growth hormone (GH) and its downstream effector, the insulin-like growth factor-1 (IGF-1) are also major determinants of peak bone mass during puberty and young adulthood, and play important roles in maintaining bone integrity during aging. A few studies in both humans and animal models suggest that in addition to the differences in sex steroid actions on bone, sex-specific effects of GH and IGF-1 play essential roles in SSD. However, the contributions of the somatotropic (GH/IGF-1) axis to SSD are controversial and data is difficult to interpret. GH/IGF-1 are pleotropic hormones that act in an endocrine and autocrine/paracrine fashion on multiple tissues, affecting body composition as well as metabolism. Thus, understanding the contribution of the somatotropic axis to SSD requires the use of mouse models that will differentiate between these two modes of action. Elucidation of the relative contribution of GH/IGF-1 axis to SSD is significant because GH is approved for the treatment of normal children with short stature and children with congenital growth disorders. Thus, if the GH/IGF-1 axis determines SSD, treatment with GH may be tailored according to sex. In the following review, we give an overview of the roles of sex steroids in determining SSD and how they may interact with the GH/IGF-1 axis in bone. We summarize several mouse models with impaired somatotropic axis and speculate on the possible contribution of that axis to SSD.

AB - The contribution of the gonadotropic axis to skeletal sexual dimorphism (SSD) was clarified in recent years. Studies with animal models of estrogen receptor (ER) or androgen receptor (AR) null mice, as well as mice with bone cell-specific ablation of ER or AR, revealed that both hormones play major roles in skeletal acquisition, and that estrogen regulates skeletal accrual in both sexes. The growth hormone (GH) and its downstream effector, the insulin-like growth factor-1 (IGF-1) are also major determinants of peak bone mass during puberty and young adulthood, and play important roles in maintaining bone integrity during aging. A few studies in both humans and animal models suggest that in addition to the differences in sex steroid actions on bone, sex-specific effects of GH and IGF-1 play essential roles in SSD. However, the contributions of the somatotropic (GH/IGF-1) axis to SSD are controversial and data is difficult to interpret. GH/IGF-1 are pleotropic hormones that act in an endocrine and autocrine/paracrine fashion on multiple tissues, affecting body composition as well as metabolism. Thus, understanding the contribution of the somatotropic axis to SSD requires the use of mouse models that will differentiate between these two modes of action. Elucidation of the relative contribution of GH/IGF-1 axis to SSD is significant because GH is approved for the treatment of normal children with short stature and children with congenital growth disorders. Thus, if the GH/IGF-1 axis determines SSD, treatment with GH may be tailored according to sex. In the following review, we give an overview of the roles of sex steroids in determining SSD and how they may interact with the GH/IGF-1 axis in bone. We summarize several mouse models with impaired somatotropic axis and speculate on the possible contribution of that axis to SSD.

KW - Bone

KW - Growth hormone receptor (GHR)

KW - Insulin-like growth factor-1 (IGF-1)

KW - Micro-computed tomography

KW - Osteocyte

KW - Parathyroid hormone (PTH)

KW - Skeletal sexual dimorphism (SSD)

UR - http://www.scopus.com/inward/record.url?scp=84960323599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960323599&partnerID=8YFLogxK

U2 - 10.1016/j.ghir.2015.12.004

DO - 10.1016/j.ghir.2015.12.004

M3 - Article

VL - 27

SP - 7

EP - 17

JO - Endocrinology and Metabolism

JF - Endocrinology and Metabolism

SN - 1096-6374

ER -